

## Reference List

1. (1958) TOBACCO smoking and cancer of the lung: statement of the British Medical Research Council. *CA Cancer J. Clin.*, **8**: 66-68.
2. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? *Biochem. Pharmacol.*, **72**: 1605-1621.
3. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, Keski-Oja J, Saarialho-Kere UK (1999) Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. *Br. J. Cancer*, **80**: 733-743.
4. Akhurst RJ (2002) TGF-beta antagonists: why suppress a tumor suppressor? *J. Clin. Invest*, **109**: 1533-1536.
5. Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer--a double-edged sword. *Trends Cell Biol.*, **11**: S44-S51.
6. Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. *Nat. Rev. Cancer*, **7**: 139-147.
7. Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J (2000) Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. *Eur. J. Biochem.*, **267**: 2624-2631.
8. Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knauper V, Docherty AJ, Becherer JD, Blobel CP, Murphy G (2002) The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. *FEBS Lett.*, **524**: 154-158.
9. Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, Docherty AJ, Murphy G (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. *FEBS Lett.*, **473**: 275-279.
10. Apte SS (2004) A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. *Int. J. Biochem. Cell Biol.*, **36**: 981-985.
11. Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. *Oncologist.*, **12**: 201-210.
12. Arribas J, Bech-Serra JJ, Santiago-Josefat B (2006) ADAMs, cell migration and cancer. *Cancer Metastasis Rev.*, **25**: 57-68.

13. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S (2002a) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. *Nat. Med.*, **8**: 35-40.
14. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S (2002c) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. *Nat. Med.*, **8**: 35-40.
15. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S (2002b) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. *Nat. Med.*, **8**: 35-40.
16. Atfi A, Dumont E, Colland F, Bonnier D, L'Helgoualc'h A, Prunier C, Ferrand N, Clement B, Wewer UM, Theret N (2007) The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. *J. Cell Biol.*, **178**: 201-208.
17. Azim HA, Jr., Ganti AK (2006) Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand? *Cancer Treat. Rev.*, **32**: 630-636.
18. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. *J. Cell Sci.*, **115**: 3719-3727.
19. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, Lopez-Otin C (2003) Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. *Nat. Genet.*, **35**: 252-257.
20. Balkwill F (2004) Cancer and the chemokine network. *Nat. Rev. Cancer*, **4**: 540-550.
21. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell*, **7**: 211-217.
22. Barcellos-Hoff MH, Ravani SA (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. *Cancer Res.*, **60**: 1254-1260.
23. Barrett AJ, Starkey PM (1973) The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. *Biochem. J.*, **133**: 709-724.
24. Bartolome RA, Galvez BG, Longo N, Baleux F, Van Muijen GN, Sanchez-Mateos P, Arroyo AG, Teixido J (2004) Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. *Cancer Res.*, **64**: 2534-2543.

25. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. *Ann. Oncol.*, **13**: 1259-1263.
26. Beacham DA, Cukierman E (2005a) Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. *Semin. Cancer Biol.*, **15**: 329-341.
27. Beacham DA, Cukierman E (2005b) Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. *Semin. Cancer Biol.*, **15**: 329-341.
28. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. *Science*, **284**: 808-812.
29. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. *Nature*, **432**: 332-337.
30. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. *J. Clin. Oncol.*, **23**: 842-849.
31. Black RA (2002) Tumor necrosis factor-alpha converting enzyme. *Int. J. Biochem. Cell Biol.*, **34**: 1-5.
32. Black RA, White JM (1998) ADAMs: focus on the protease domain. *Curr. Opin. Cell Biol.*, **10**: 654-659.
33. Blobel CP (1997) Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. *Cell*, **90**: 589-592.
34. Blobel CP (2002) Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. *Inflamm. Res.*, **51**: 83-84.
35. Blobel CP, Myles DG, Primakoff P, White JM (1990a) Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence. *J. Cell Biol.*, **111**: 69-78.
36. Blobel CP, Myles DG, Primakoff P, White JM (1990b) Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence. *J. Cell Biol.*, **111**: 69-78.
37. Blobel CP, Wolfsberg TG, Turck CW, Myles DG, Primakoff P, White JM (1992) A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. *Nature*, **356**: 248-252.
38. Bode W, Gomis-Ruth FX, Stockler W (1993) Astacins, serralyisins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. *FEBS Lett.*, **331**: 134-140.

39. Bode W, Maskos K (2003) Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. *Biol. Chem.*, **384**: 863-872.
40. Borm PJ, Driscoll K (1996) Particles, inflammation and respiratory tract carcinogenesis. *Toxicol. Lett.*, **88**: 109-113.
41. Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY, Moro-Sibilot D (2003) Early detection of lung cancer: role of biomarkers. *Eur. Respir. J. Suppl*, **39**: 36s-44s.
42. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. *Eur. Respir. J.*, **18**: 1059-1068.
43. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW (2002) Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. *Br. J. Cancer*, **86**: 1864-1870.
44. Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, Goke B, Eichhorst ST (2005) CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. *Exp. Cell Res.*, **310**: 117-130.
45. Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. *Lung Cancer*, **51**: 143-158.
46. Burri PH, Djonov V (2002) Intussusceptive angiogenesis--the alternative to capillary sprouting. *Mol. Aspects Med.*, **23**: S1-27.
47. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C (2002) Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. *Gene*, **283**: 49-62.
48. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C (2005) The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. *Int. J. Oncol.*, **26**: 17-24.
49. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. *Nat. Med.*, **6**: 389-395.
50. Cauwe B, Steen PE, Opdenakker G (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. *Crit Rev. Biochem. Mol. Biol.*, **42**: 113-185.
51. Cawston TE, Wilson AJ (2006) Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. *Best. Pract. Res. Clin. Rheumatol.*, **20**: 983-1002.

52. Chabottaux V, Sounni NE, Pennington CJ, English WR, van den BF, Blacher S, Gilles C, Munaut C, Maquoi E, Lopez-Otin C, Murphy G, Edwards DR, Foidart JM, Noel A (2006) Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. *Cancer Res.*, **66**: 5165-5172.
53. Chan SK, Hill ME, Gullick WJ (2006) The role of the epidermal growth factor receptor in breast cancer. *J. Mammary. Gland. Biol. Neoplasia.*, **11**: 3-11.
54. Cheng JD, Weiner LM (2003) Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibroutuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. *Clin. Cancer Res.*, **9**: 1639-1647, 2003. *Clin. Cancer Res.*, **9**: 1590-1595.
55. Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP (2003) Catalytic properties of ADAM19. *J. Biol. Chem.*, **278**: 22331-22340.
56. Colige A, Beschin A, Samyn B, Goebels Y, Van Beeumen J, Nusgens BV, Lapiere CM (1995b) Characterization and partial amino acid sequencing of a 107-kDa procollagen I N-proteinase purified by affinity chromatography on immobilized type XIV collagen. *J. Biol. Chem.*, **270**: 16724-16730.
57. Colige A, Beschin A, Samyn B, Goebels Y, Van Beeumen J, Nusgens BV, Lapiere CM (1995a) Characterization and partial amino acid sequencing of a 107-kDa procollagen I N-proteinase purified by affinity chromatography on immobilized type XIV collagen. *J. Biol. Chem.*, **270**: 16724-16730.
58. Colige A, Sieron AL, Li SW, Schwarze U, Petty E, Wertelecki W, Wilcox W, Krakow D, Cohn DH, Reardon W, Byers PH, Lapiere CM, Prockop DJ, Nusgens BV (1999) Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. *Am. J. Hum. Genet.*, **65**: 308-317.
59. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH (1997) The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. *J. Pathol.*, **181**: 401-404.
60. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science*, **295**: 2387-2392.
61. Coussens LM, Werb Z (2002) Inflammation and cancer. *Nature*, **420**: 860-867.
62. De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. *J. Pathol.*, **200**: 429-447.
63. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. *Cancer Metastasis Rev.*, **25**: 9-34.
64. DOLL R, HILL AB (1950) Smoking and carcinoma of the lung; preliminary report. *Br. Med. J.*, **2**: 739-748.
65. Dunn JR, Panutsopoulos D, Shaw MW, Heighway J, Dormer R, Salmo EN, Watson SG, Field JK, Liloglou T (2004c) METH-2 silencing and promoter hypermethylation in NSCLC. *Br. J. Cancer*, **91**: 1149-1154.

66. Dunn JR, Panutsopoulos D, Shaw MW, Heighway J, Dormer R, Salmo EN, Watson SG, Field JK, Liloglou T (2004b) METH-2 silencing and promoter hypermethylation in NSCLC. *Br. J. Cancer*, **91**: 1149-1154.
67. Dunn JR, Panutsopoulos D, Shaw MW, Heighway J, Dormer R, Salmo EN, Watson SG, Field JK, Liloglou T (2004a) METH-2 silencing and promoter hypermethylation in NSCLC. *Br. J. Cancer*, **91**: 1149-1154.
68. Dunn JR, Reed JE, du Plessis DG, Shaw EJ, Reeves P, Gee AL, Warnke P, Walker C (2006) Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. *Br. J. Cancer*, **94**: 1186-1193.
69. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N. Engl. J. Med.*, **315**: 1650-1659.
70. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. *Nat. Rev. Cancer*, **2**: 161-174.
71. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. *Genes Dev.*, **15**: 50-65.
72. Emi M, Katagiri T, Harada Y, Saito H, Inazawa J, Ito I, Kasumi F, Nakamura Y (1993) A novel metalloprotease/disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. *Nat. Genet.*, **5**: 151-157.
73. Eto K, Huet C, Tarui T, Kupriyanov S, Liu HZ, Puzon-McLaughlin W, Zhang XP, Sheppard D, Engvall E, Takada Y (2002b) Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions. *J. Biol. Chem.*, **277**: 17804-17810.
74. Eto K, Huet C, Tarui T, Kupriyanov S, Liu HZ, Puzon-McLaughlin W, Zhang XP, Sheppard D, Engvall E, Takada Y (2002a) Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions. *J. Biol. Chem.*, **277**: 17804-17810.
75. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E (2001) Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. *Semin. Oncol.*, **28**: 620-625.
76. Fernandes RJ, Hirohata S, Engle JM, Colige A, Cohn DH, Eyre DR, Apte SS (2001) Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. *J. Biol. Chem.*, **276**: 31502-31509.
77. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. *Oncogene*, **23**: 157-167.
78. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. *Int. J. Dev. Biol.*, **48**: 411-424.

79. Folkman J (2001) Angiogenesis-dependent diseases. *Semin. Oncol.*, **28**: 536-542.
80. Frohlich C, Albrechtsen R, Dyrskjot L, Rudkjaer L, Orntoft TF, Wewer UM (2006a) Molecular profiling of ADAM12 in human bladder cancer. *Clin. Cancer Res.*, **12**: 7359-7368.
81. Frohlich C, Albrechtsen R, Dyrskjot L, Rudkjaer L, Orntoft TF, Wewer UM (2006b) Molecular profiling of ADAM12 in human bladder cancer. *Clin. Cancer Res.*, **12**: 7359-7368.
82. Fromigue O, Louis K, Dayem M, Milanini J, Pages G, Tartare-Deckert S, Ponzio G, Hofman P, Barbry P, Auberger P, Mari B (2003) Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival. *Oncogene*, **22**: 8487-8497.
83. Fujino H, Kondo K, Ishikura H, Maki H, Kinoshita H, Miyoshi T, Takahashi Y, Sawada N, Takizawa H, Nagao T, Sakiyama S, Monden Y (2005) Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer. *Mol. Cancer Ther.*, **4**: 1409-1416.
84. Gee JM, Knowlden JM (2003) ADAM metalloproteases and EGFR signalling. *Breast Cancer Res.*, **5**: 223-224.
85. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. *J. Clin. Oncol.*, **23**: 3235-3242.
86. Giaccone G (2007) The potential of antiangiogenic therapy in non-small cell lung cancer. *Clin. Cancer Res.*, **13**: 1961-1970.
87. Giatromanolaki A, Sivridis E, Koukourakis MI (2007) The Pathology of Tumor Stromatogenesis. *Cancer Biol. Ther.*, **6**.
88. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM (1998e) A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. *J. Biol. Chem.*, **273**: 157-166.
89. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM (1998b) A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. *J. Biol. Chem.*, **273**: 157-166.
90. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM (1998c) A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. *J. Biol. Chem.*, **273**: 157-166.
91. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM (1998d) A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. *J. Biol. Chem.*, **273**: 157-166.
92. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM (1998a) A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. *J. Biol. Chem.*, **273**: 157-166.

93. Gorrin-Rivas MJ, Aarii S, Furutani M, Mizumoto M, Mori A, Hanaki K, Maeda M, Furuyama H, Kondo Y, Imamura M (2000) Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. *Clin. Cancer Res.*, **6**: 1647-1654.
94. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res.*, **54**: 4855-4878.
95. GROSS J, Lapiere CM (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. *Proc. Natl. Acad. Sci. U. S. A.*, **48**: 1014-1022.
96. Grossi F, Aita M (2007) Bevacizumab and non-small-cell lung cancer: starving the enemy to survive. *Expert. Opin. Biol. Ther.*, **7**: 1107-1119.
97. Gutierrez-Fernandez A, Inada M, Balbin M, Fueyo A, Pitiot AS, Astudillo A, Hirose K, Hirata M, Shapiro SD, Noel A, Werb Z, Krane SM, Lopez-Otin C, Puente XS (2007) Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). *FASEB J.*, **21**: 2580-2591.
98. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell*, **86**: 353-364.
99. Hanahan D, Weinberg RA (2000b) The hallmarks of cancer. *Cell*, **100**: 57-70.
100. Hanahan D, Weinberg RA (2000a) The hallmarks of cancer. *Cell*, **100**: 57-70.
101. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. *Exp. Cell Res.*, **284**: 2-13.
102. Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. *Cancer Res.*, **64**: 1943-1950.
103. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena IA, von Figura K, Saftig P (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. *Hum. Mol. Genet.*, **11**: 2615-2624.
104. Hawthorn L, Stein L, Panzarella J, Loewen GM, Baumann H (2006b) Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. *Lung Cancer*, **53**: 129-142.
105. Hawthorn L, Stein L, Panzarella J, Loewen GM, Baumann H (2006a) Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. *Lung Cancer*, **53**: 129-142.
106. Helmig S, Schneider J (2007) Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer. *Expert. Rev. Mol. Diagn.*, **7**: 555-568.



107. Hensel CH, Hsieh CL, Gazdar AF, Johnson BE, Sakaguchi AY, Naylor SL, Lee WH, Lee EY (1990) Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. *Cancer Res.*, **50**: 3067-3072.
108. Higashiyama S, Nanba D (2005a) ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. *Biochim. Biophys. Acta*, **1751**: 110-117.
109. Higashiyama S, Nanba D (2005b) ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. *Biochim. Biophys. Acta*, **1751**: 110-117.
110. Hoang CD, D'Cunha J, Tawfic SH, Gruessner AC, Kratzke RA, Maddaus MA (2004) Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden. *J. Thorac. Cardiovasc. Surg.*, **127**: 1332-1341.
111. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruitter DJ, Van Muijen GN (2000) Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. *J. Pathol.*, **191**: 245-256.
112. Holbro T, Hynes NE (2004) ErbB receptors: directing key signaling networks throughout life. *Annu. Rev. Pharmacol. Toxicol.*, **44**: 195-217.
113. Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, Cornelius LA, Shapiro SD (2006) Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. *Cancer Res.*, **66**: 6149-6155.
114. Howard L, Maciewicz RA, Blobel CP (2000) Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. *Biochem. J.*, **348 Pt 1**: 21-27.
115. Huovila AP, Almeida EA, White JM (1996) ADAMs and cell fusion. *Curr. Opin. Cell Biol.*, **8**: 692-699.
116. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM (2005a) Shedding light on ADAM metalloproteinases. *Trends Biochem. Sci.*, **30**: 413-422.
117. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM (2005b) Shedding light on ADAM metalloproteinases. *Trends Biochem. Sci.*, **30**: 413-422.
118. Iba K, Albrechtsen R, Gilpin B, Frohlich C, Loechel F, Zolkiewska A, Ishiguro K, Kojima T, Liu W, Langford JK, Sanderson RD, Brakebusch C, Fassler R, Wewer UM (2000) The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. *J. Cell Biol.*, **149**: 1143-1156.
119. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM (1999) Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. *Am. J. Pathol.*, **154**: 1489-1501.
120. Iruela-Arispe ML, Carpizo D, Luque A (2003b) ADAMTS1: a matrix metalloprotease with angioinhibitory properties. *Ann. N. Y. Acad. Sci.*, **995**: 183-190.

121. Iruela-Arispe ML, Carpizo D, Luque A (2003a) ADAMTS1: a matrix metalloprotease with angioinhibitory properties. *Ann. N. Y. Acad. Sci.*, **995**: 183-190.
122. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y (2004a) ADAM8 as a novel serological and histochemical marker for lung cancer. *Clin. Cancer Res.*, **10**: 8363-8370.
123. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y (2004b) ADAM8 as a novel serological and histochemical marker for lung cancer. *Clin. Cancer Res.*, **10**: 8363-8370.
124. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y (2004c) ADAM8 as a novel serological and histochemical marker for lung cancer. *Clin. Cancer Res.*, **10**: 8363-8370.
125. Itoh Y, Nagase H (2002) Matrix metalloproteinases in cancer. *Essays Biochem.*, **38**: 21-36.
126. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E (1998) A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. *EMBO J.*, **17**: 7260-7272.
127. Johnson BE, Makuch RW, Simmons AD, Gazdar AF, Burch D, Cashell AW (1988) myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. *Cancer Res.*, **48**: 5163-5166.
128. Jonsson-Rylander AC, Nilsson T, Fritsche-Danielson R, Hammarstrom A, Behrendt M, Andersson JO, Lindgren K, Andersson AK, Wallbrandt P, Rosengren B, Brodin P, Thelin A, Westin A, Hurt-Camejo E, Lee-Sogaard CH (2005) Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. *Arterioscler. Thromb. Vasc. Biol.*, **25**: 180-185.
129. Jost M, Folgueras AR, Frerart F, Pendas AM, Blacher S, Houard X, Berndt S, Munaut C, Cataldo D, Alvarez J, Melen-Lamalle L, Foidart JM, Lopez-Otin C, Noel A (2006) Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. *Cancer Res.*, **66**: 5234-5241.
130. Kalluri R, Zeisberg M (2006a) Fibroblasts in cancer. *Nat. Rev. Cancer*, **6**: 392-401.
131. Kalluri R, Zeisberg M (2006d) Fibroblasts in cancer. *Nat. Rev. Cancer*, **6**: 392-401.
132. Kalluri R, Zeisberg M (2006c) Fibroblasts in cancer. *Nat. Rev. Cancer*, **6**: 392-401.
133. Kalluri R, Zeisberg M (2006b) Fibroblasts in cancer. *Nat. Rev. Cancer*, **6**: 392-401.
134. Kang Q, Cao Y, Zolkiewska A (2001) Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells. *J. Biol. Chem.*, **276**: 24466-24472.

135. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell*, **3**: 537-549.
136. Kaspar M, Zardi L, Neri D (2006) Fibronectin as target for tumor therapy. *Int. J. Cancer*, **118**: 1331-1339.
137. Kawaguchi N, Xu X, Tajima R, Kronqvist P, Sundberg C, Loechel F, Albrechtsen R, Wewer UM (2002a) ADAM 12 protease induces adipogenesis in transgenic mice. *Am. J. Pathol.*, **160**: 1895-1903.
138. Kawaguchi N, Xu X, Tajima R, Kronqvist P, Sundberg C, Loechel F, Albrechtsen R, Wewer UM (2002b) ADAM 12 protease induces adipogenesis in transgenic mice. *Am. J. Pathol.*, **160**: 1895-1903.
139. Kaye FJ (2001c) Molecular biology of lung cancer. *Lung Cancer*, **34 Suppl 2**: S35-S41.
140. Kaye FJ (2001a) Molecular biology of lung cancer. *Lung Cancer*, **34 Suppl 2**: S35-S41.
141. Kaye FJ (2001b) Molecular biology of lung cancer. *Lung Cancer*, **34 Suppl 2**: S35-S41.
142. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R (2002) Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. *Cancer Res.*, **62**: 6304-6311.
143. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, Shin BA, Ahn BW, Jung YD (2004) EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. *Anticancer Res.*, **24**: 747-753.
144. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G (1996) Biochemical characterization of human collagenase-3. *J. Biol. Chem.*, **271**: 1544-1550.
145. Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T, Yoshida K, Nakada M, Ohuchi E, Okada Y (2004b) ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. *Am. J. Pathol.*, **165**: 1743-1753.
146. Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T, Yoshida K, Nakada M, Ohuchi E, Okada Y (2004a) ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. *Am. J. Pathol.*, **165**: 1743-1753.
147. Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T, Yoshida K, Nakada M, Ohuchi E, Okada Y (2004c) ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. *Am. J. Pathol.*, **165**: 1743-1753.

148. Krampert M, Kuenzle S, Thai SN, Lee N, Iruela-Arispe ML, Werner S (2005) ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. *J. Biol. Chem.*, **280**: 23844-23852.
149. Krystal GW, Hines SJ, Organ CP (1996) Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. *Cancer Res.*, **56**: 370-376.
150. Kulbe H, Levinson NR, Balkwill F, Wilson JL (2004) The chemokine network in cancer--much more than directing cell movement. *Int. J. Dev. Biol.*, **48**: 489-496.
151. Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K (2004a) The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. *Biochem. Biophys. Res. Commun.*, **319**: 1327-1333.
152. Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K (2004b) The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. *Biochem. Biophys. Res. Commun.*, **319**: 1327-1333.
153. Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K (2004c) The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. *Biochem. Biophys. Res. Commun.*, **319**: 1327-1333.
154. Kuno K, Iizasa H, Ohno S, Matsushima K (1997a) The exon/intron organization and chromosomal mapping of the mouse ADAMTS-1 gene encoding an ADAM family protein with TSP motifs. *Genomics*, **46**: 466-471.
155. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K (1997b) Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. *J. Biol. Chem.*, **272**: 556-562.
156. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K (1997c) Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. *J. Biol. Chem.*, **272**: 556-562.
157. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K (1997d) Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. *J. Biol. Chem.*, **272**: 556-562.
158. Kuno K, Matsushima K (1998) ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. *J. Biol. Chem.*, **273**: 13912-13917.
159. Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, Matsushima K (2000) ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. *FEBS Lett.*, **478**: 241-245.
160. Kuno K, Terashima Y, Matsushima K (1999) ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. *J. Biol. Chem.*, **274**: 18821-18826.

161. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. *Proc. Natl. Acad. Sci. U. S. A.*, **101**: 4966-4971.
162. Kurisaki T, Masuda A, Sudo K, Sakagami J, Higashiyama S, Matsuda Y, Nagabukuro A, Tsuji A, Nabeshima Y, Asano M, Iwakura Y, Sehara-Fujisawa A (2003) Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis. *Mol. Cell Biol.*, **23**: 55-61.
163. Kveiborg M, Albrechtsen R, Rudkjaer L, Wen G, Damgaard-Pedersen K, Wewer UM (2006) ADAM12-S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation. *J. Bone Miner. Res.*, **21**: 1288-1296.
164. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P, Kronqvist P, Rank F, Mercurio AM, Wewer UM (2005a) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. *Cancer Res.*, **65**: 4754-4761.
165. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P, Kronqvist P, Rank F, Mercurio AM, Wewer UM (2005b) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. *Cancer Res.*, **65**: 4754-4761.
166. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P, Kronqvist P, Rank F, Mercurio AM, Wewer UM (2005c) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. *Cancer Res.*, **65**: 4754-4761.
167. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P, Kronqvist P, Rank F, Mercurio AM, Wewer UM (2005d) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. *Cancer Res.*, **65**: 4754-4761.
168. Laigaard J, Christiansen M, Frohlich C, Pedersen BN, Ottesen B, Wewer UM (2005a) The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. *Prenat. Diagn.*, **25**: 45-46.
169. Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, Sundberg K, Shalmi AC, Tabor A, Norgaard-Pedersen B, Ottesen B, Christiansen M, Wewer UM (2005b) Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. *Obstet. Gynecol.*, **106**: 144-149.
170. Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, Wewer UM (2006) ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. *Prenat. Diagn.*, **26**: 973-979.
171. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E (2003) Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. *Clin. Lung Cancer*, **4**: 231-236.
172. Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, Baffet G, Clement B, Theret N (2003a) ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. *Hepatology*, **37**: 1056-1066.

173. Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, Baffet G, Clement B, Theret N (2003b) ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. *Hepatology*, **37**: 1056-1066.
174. Le Pabic H, L'Helgoualc'h A, Coutant A, Wewer UM, Baffet G, Clement B, Theret N (2005) Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. *J. Hepatol.*, **43**: 1038-1044.
175. Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, Iruela-Arispe ML (2006) ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. *EMBO J.*, **25**: 5270-5283.
176. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C (2003a) Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. *J. Biol. Chem.*, **278**: 26202-26207.
177. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C (2003b) Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. *J. Biol. Chem.*, **278**: 26202-26207.
178. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C (2003c) Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. *J. Biol. Chem.*, **278**: 26202-26207.
179. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C (2003d) Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. *J. Biol. Chem.*, **278**: 26202-26207.
180. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. *J. Cancer Res. Clin. Oncol.*, **131**: 41-48.
181. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. *Cell*, **88**: 323-331.
182. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr., Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature*, **413**: 488-494.
183. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. *Nature*, **411**: 375-379.
184. Liu D, Hornsby PJ (2007) Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. *Cancer Res.*, **67**: 3117-3126.
185. Liu YJ, Xu Y, Yu Q (2006b) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.

186. Liu YJ, Xu Y, Yu Q (2006c) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.
187. Liu YJ, Xu Y, Yu Q (2006d) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.
188. Liu YJ, Xu Y, Yu Q (2006e) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.
189. Liu YJ, Xu Y, Yu Q (2006f) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.
190. Liu YJ, Xu Y, Yu Q (2006g) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.
191. Liu YJ, Xu Y, Yu Q (2006a) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. *Oncogene*, **25**: 2452-2467.
192. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM (2000) ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. *Biochem. Biophys. Res. Commun.*, **278**: 511-515.
193. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM (1998c) Human ADAM 12 (meltrin alpha) is an active metalloprotease. *J. Biol. Chem.*, **273**: 16993-16997.
194. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM (1998a) Human ADAM 12 (meltrin alpha) is an active metalloprotease. *J. Biol. Chem.*, **273**: 16993-16997.
195. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM (1998b) Human ADAM 12 (meltrin alpha) is an active metalloprotease. *J. Biol. Chem.*, **273**: 16993-16997.
196. Longpre JM, Leduc R (2004) Identification of prodomain determinants involved in ADAMTS-1 biosynthesis. *J. Biol. Chem.*, **279**: 33237-33245.
197. Lopez-Otin C, Matrisian LM (2007c) Emerging roles of proteases in tumour suppression. *Nat. Rev. Cancer*, **7**: 800-808.
198. Lopez-Otin C, Matrisian LM (2007d) Emerging roles of proteases in tumour suppression. *Nat. Rev. Cancer*, **7**: 800-808.
199. Lopez-Otin C, Matrisian LM (2007a) Emerging roles of proteases in tumour suppression. *Nat. Rev. Cancer*, **7**: 800-808.
200. Lopez-Otin C, Matrisian LM (2007b) Emerging roles of proteases in tumour suppression. *Nat. Rev. Cancer*, **7**: 800-808.
201. Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. *Mol. Cancer Res.*, **4**: 221-233.
202. Luque A, Carpizo DR, Iruela-Arispe ML (2003b) ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. *J. Biol. Chem.*, **278**: 23656-23665.

203. Luque A, Carpizo DR, Iruela-Arispe ML (2003a) ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. *J. Biol. Chem.*, **278**: 23656-23665.
204. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C (2004) The stroma as a crucial target in rat mammary gland carcinogenesis. *J. Cell Sci.*, **117**: 1495-1502.
205. Martin MD, Matrisian LM (2007c) The other side of MMPs: protective roles in tumor progression. *Cancer Metastasis Rev.*, **26**: 717-724.
206. Martin MD, Matrisian LM (2007b) The other side of MMPs: protective roles in tumor progression. *Cancer Metastasis Rev.*, **26**: 717-724.
207. Martin MD, Matrisian LM (2007a) The other side of MMPs: protective roles in tumor progression. *Cancer Metastasis Rev.*, **26**: 717-724.
208. Masaki M, Kurisaki T, Shirakawa K, Sehara-Fujisawa A (2005) Role of meltrin {alpha} (ADAM12) in obesity induced by high-fat diet. *Endocrinology*, **146**: 1752-1763.
209. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, Basset P, Rio MC (1998) In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. *J. Cell Biol.*, **140**: 1535-1541.
210. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, Arii S, Doi R, Imamura M (2001b) Expression of METH-1 and METH-2 in pancreatic cancer. *Clin. Cancer Res.*, **7**: 3437-3443.
211. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, Arii S, Doi R, Imamura M (2001a) Expression of METH-1 and METH-2 in pancreatic cancer. *Clin. Cancer Res.*, **7**: 3437-3443.
212. Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, Toker A (2005) A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. *Cancer Res.*, **65**: 4728-4738.
213. McCawley LJ, Crawford HC, King LE, Jr., Mudgett J, Matrisian LM (2004) A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. *Cancer Res.*, **64**: 6965-6972.
214. Miguel RF, Pollak A, Lubec G (2005) Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease. *Brain Res. Mol. Brain Res.*, **133**: 1-5.
215. Millichip MI, Dallas DJ, Wu E, Dale S, McKie N (1998) The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. *Biochem. Biophys. Res. Commun.*, **245**: 594-598.



216. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J (2005b) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *J. Clin. Invest.*, **115**: 44-55.
217. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J (2005a) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *J. Clin. Invest.*, **115**: 44-55.
218. Mittaz L, Russell DL, Wilson T, Brasted M, Tkalcevic J, Salamonsen LA, Hertzog PJ, Pritchard MA (2004b) Adamts-1 is essential for the development and function of the urogenital system. *Biol. Reprod.*, **70**: 1096-1105.
219. Mittaz L, Russell DL, Wilson T, Brasted M, Tkalcevic J, Salamonsen LA, Hertzog PJ, Pritchard MA (2004a) Adamts-1 is essential for the development and function of the urogenital system. *Biol. Reprod.*, **70**: 1096-1105.
220. Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and progression. *Cancer Sci.*, **98**: 621-628.
221. Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y (2004) ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. *Biochem. Biophys. Res. Commun.*, **315**: 79-84.
222. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA (2000) Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. *Cancer Res.*, **60**: 2562-2566.
223. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD, . (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. *Nature*, **385**: 733-736.
224. Mueller MM, Fusenig NE (2002) Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. *Differentiation*, **70**: 486-497.
225. Mueller MM, Fusenig NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. *Nat. Rev. Cancer*, **4**: 839-849.
226. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. *Nature*, **410**: 50-56.
227. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. *Biol. Chem.*, **378**: 151-160.
228. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc. Res.*, **69**: 562-573.

229. Nguyen DX, Massague J (2007b) Genetic determinants of cancer metastasis. *Nat. Rev. Genet.*, **8**: 341-352.
230. Nguyen DX, Massague J (2007a) Genetic determinants of cancer metastasis. *Nat. Rev. Genet.*, **8**: 341-352.
231. Noel A, Foidart JM (1998) The role of stroma in breast carcinoma growth in vivo. *J. Mammary. Gland. Biol. Neoplasia.*, **3**: 215-225.
232. Noel A, Jost M, Maquoi E (2008a) Matrix metalloproteinases at cancer tumor-host interface. *Semin. Cell Dev. Biol.*, **19**: 52-60.
233. Noel A, Jost M, Maquoi E (2008b) Matrix metalloproteinases at cancer tumor-host interface. *Semin. Cell Dev. Biol.*, **19**: 52-60.
234. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM (2004a) Membrane associated proteases and their inhibitors in tumour angiogenesis. *J. Clin. Pathol.*, **57**: 577-584.
235. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM (2004b) Membrane associated proteases and their inhibitors in tumour angiogenesis. *J. Clin. Pathol.*, **57**: 577-584.
236. Noel A, Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM (1993a) Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. *Br. J. Cancer*, **68**: 909-915.
237. Noel A, Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM (1993b) Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. *Br. J. Cancer*, **68**: 909-915.
238. Noel A, Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM (1993c) Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. *Br. J. Cancer*, **68**: 909-915.
239. Noel AC, Lefebvre O, Maquoi E, VanHoorde L, Chenard MP, Mareel M, Foidart JM, Basset P, Rio MC (1996) Stromelysin-3 expression promotes tumor take in nude mice. *J. Clin. Invest*, **97**: 1924-1930.
240. Ogata Y, Matono K, Nakajima M, Sasatomi T, Mizobe T, Nagase H, Shirouzu K (2006) Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat. *Int. J. Cancer*, **118**: 215-221.
241. Ohtsu H, Dempsey PJ, Eguchi S (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. *Am. J. Physiol Cell Physiol*, **291**: C1-10.
242. Ohtsuka T, Shiomi T, Shimoda M, Kodama T, Amour A, Murphy G, Ohuchi E, Kobayashi K, Okada Y (2006a) ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. *Int. J. Cancer*, **118**: 263-273.

243. Ohtsuka T, Shiomi T, Shimoda M, Kodama T, Amour A, Murphy G, Ohuchi E, Kobayashi K, Okada Y (2006b) ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. *Int. J. Cancer*, **118**: 263-273.
244. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. *Cancer Res.*, **59**: 5002-5011.
245. Orimo A, Gupta PB, SgROI DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell*, **121**: 335-348.
246. Osann KE (1998) Epidemiology of lung cancer. *Curr. Opin. Pulm. Med.*, **4**: 198-204.
247. Overall CM (2002) Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. *Mol. Biotechnol.*, **22**: 51-86.
248. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. *Nat. Rev. Cancer*, **2**: 657-672.
249. Paget S. The distribution of secondary growths in cancer of the breast. *The Lancet* 133, 571-573. 1889.
- Ref Type: Generic
250. Pardali K, Moustakas A (2007) Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. *Biochim. Biophys. Acta*, **1775**: 21-62.
251. Park BB, Park JO, Kim H, Ahn YC, Choi YS, Kim K, Kim J, Shim YM, Ahn JS, Park K (2006) Is trimodality approach better than bimodality in stage IIIA, N2 positive non-small cell lung cancer? *Lung Cancer*, **53**: 323-330.
252. Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI, Blobel CP (2006) ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. *Oncogene*, **25**: 5462-5466.
253. Pendas AM, Balbin M, Llano E, Jimenez MG, Lopez-Otin C (1997) Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). *Genomics*, **40**: 222-233.
254. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. *J. Clin. Oncol.*, **22**: 330-353.
255. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. *Am. J. Respir. Crit Care Med.*, **167**: 1676-1686.

256. Porter S, Clark IM, Kevorkian L, Edwards DR (2005a) The ADAMTS metalloproteinases. *Biochem. J.*, **386**: 15-27.
257. Porter S, Clark IM, Kevorkian L, Edwards DR (2005b) The ADAMTS metalloproteinases. *Biochem. J.*, **386**: 15-27.
258. Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR (2004a) Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. *Clin. Cancer Res.*, **10**: 2429-2440.
259. Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR (2004b) Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. *Clin. Cancer Res.*, **10**: 2429-2440.
260. Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR (2004c) Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. *Clin. Cancer Res.*, **10**: 2429-2440.
261. Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR (2004d) Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. *Clin. Cancer Res.*, **10**: 2429-2440.
262. Potti A, Willardson J, Forseen C, Kishor GA, Koch M, Hebert B, Levitt R, Mehdi SA (2002) Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. *Lung Cancer*, **36**: 257-261.
263. Primakoff P, Myles DG (2000b) The ADAM gene family: surface proteins with adhesion and protease activity. *Trends Genet.*, **16**: 83-87.
264. Primakoff P, Myles DG (2000a) The ADAM gene family: surface proteins with adhesion and protease activity. *Trends Genet.*, **16**: 83-87.
265. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C (2003) Human and mouse proteases: a comparative genomic approach. *Nat. Rev. Genet.*, **4**: 544-558.
266. Qi H, Rand MD, Wu X, Sestan N, Wang W, Rakic P, Xu T, Artavanis-Tsakonas S (1999) Processing of the notch ligand delta by the metalloprotease Kuzbanian. *Science*, **283**: 91-94.
267. Qu X, Yuan Y, Xu W, Chen M, Cui S, Meng H, Li Y, Makuuchi M, Nakata M, Tang W (2006a) Caffeoyle pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. *Anticancer Res.*, **26**: 3573-3578.
268. Qu XJ, Yuan YX, Tian ZG, Xu WF, Chen MH, Cui SX, Guo Q, Gai R, Makuuchi M, Nakata M, Tang W (2006b) Using caffeoyle pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis. *Int. J. Mol. Med.*, **18**: 609-614.

269. Reiss K, Ludwig A, Saftig P (2006) Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. *Pharmacol. Ther.*, **111**: 985-1006.
270. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ (1993) Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. *Oncogene*, **8**: 1913-1919.
271. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D (2008a) Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. *Biochimie*, **90**: 369-379.
272. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D (2008b) Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. *Biochimie*, **90**: 369-379.
273. Rocks N, Paulissen G, Quesada CF, Polette M, Gueders M, Munaut C, Foidart JM, Noel A, Birembaut P, Cataldo D (2006a) Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). *Br. J. Cancer*, **94**: 724-730.
274. Rocks N, Paulissen G, Quesada CF, Polette M, Gueders M, Munaut C, Foidart JM, Noel A, Birembaut P, Cataldo D (2006b) Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). *Br. J. Cancer*, **94**: 724-730.
275. Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, Leduc R, Iruela-Arispe ML (2000a) Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. *J. Biol. Chem.*, **275**: 33471-33479.
276. Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, Leduc R, Iruela-Arispe ML (2000b) Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. *J. Biol. Chem.*, **275**: 33471-33479.
277. Rodriguez-Manzaneque JC, Westling J, Thai SN, Luque A, Knauper V, Murphy G, Sandy JD, Iruela-Arispe ML (2002) ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. *Biochem. Biophys. Res. Commun.*, **293**: 501-508.
278. Ronnov-Jessen L, Petersen OW (1993) Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. *Lab Invest*, **68**: 696-707.
279. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA (2004a) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. *J. Biol. Chem.*, **279**: 51323-51330.
280. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA (2004b) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. *J. Biol. Chem.*, **279**: 51323-51330.

281. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M (2007) Manipulating the chemokine-chemokine receptor network to treat cancer. *Cancer*, **109**: 2392-2404.
282. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev. Oncol. Hematol.*, **19**: 183-232.
283. Sanderson MP, Dempsey PJ, Dunbar AJ (2006) Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. *Growth Factors*, **24**: 121-136.
284. Scagliotti GV, Selvaggi G (2006) The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management. *Rev. Mal Respir.*, **23**: 16S137-16S147.
285. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N. Engl. J. Med.*, **346**: 92-98.
286. Schlesselman JJ (2006) The emerging case-control study: lung cancer in relation to tobacco smoking. *Prev. Med.*, **43**: 251-255.
287. Schlomann U, Wildeboer D, Webster A, Antropova O, Zeuschner D, Knight CG, Docherty AJ, Lambert M, Skelton L, Jockusch H, Bartsch JW (2002) The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. *J. Biol. Chem.*, **277**: 48210-48219.
288. Schutz A, Hartig W, Wobus M, Grosche J, Wittekind C, Aust G (2005) Expression of ADAM15 in lung carcinomas. *Virchows Arch.*, **446**: 421-429.
289. Seals DF, Courtneidge SA (2003c) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev.*, **17**: 7-30.
290. Seals DF, Courtneidge SA (2003d) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev.*, **17**: 7-30.
291. Seals DF, Courtneidge SA (2003e) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev.*, **17**: 7-30.
292. Seals DF, Courtneidge SA (2003b) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev.*, **17**: 7-30.
293. Seals DF, Courtneidge SA (2003a) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev.*, **17**: 7-30.
294. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezzak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. *N. Engl. J. Med.*, **353**: 123-132.

295. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ (2000) ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. *J. Biol. Chem.*, **275**: 18574-18580.
296. Shinoda K, Shibuya M, Hibino S, Ono Y, Matsuda K, Takemura A, Zou D, Kokubo Y, Takechi A, Kudoh S (2003) A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line. *Int. J. Oncol.*, **22**: 281-288.
297. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H, Matsuura N (2004) Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. *Cancer Res.*, **64**: 4190-4196.
298. Shozu M, Minami N, Yokoyama H, Inoue M, Kurihara H, Matsushima K, Kuno K (2005) ADAMTS-1 is involved in normal follicular development, ovulatory process and organization of the medullary vascular network in the ovary. *J. Mol. Endocrinol.*, **35**: 343-355.
299. Silvestri GA, Rivera MP (2005b) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. *Chest*, **128**: 3975-3984.
300. Silvestri GA, Rivera MP (2005a) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. *Chest*, **128**: 3975-3984.
301. Skotnicki JS, DiGrandi MJ, Levin JI (2003) Design strategies for the identification of MMP-13 and Tace inhibitors. *Curr. Opin. Drug Discov. Devel.*, **6**: 742-759.
302. Smith PW, Denlinger CE, Jones DR (2006) Novel targeted therapies for non-small cell lung cancer. *Thorac. Surg. Clin.*, **16**: 353-366.
303. Sounni NE, Noel A (2005) Membrane type-matrix metalloproteinases and tumor progression. *Biochimie*, **87**: 329-342.
304. Spencer K, Cowans NJ (2007) ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy. *J. Matern. Fetal Neonatal Med.*, **20**: 645-650.
305. Stocker W, Bode W (1995b) Structural features of a superfamily of zinc-endopeptidases: the metzincins. *Curr. Opin. Struct. Biol.*, **5**: 383-390.
306. Stocker W, Bode W (1995a) Structural features of a superfamily of zinc-endopeptidases: the metzincins. *Curr. Opin. Struct. Biol.*, **5**: 383-390.
307. Stone AL, Kroeger M, Sang QX (1999) Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). *J. Protein Chem.*, **18**: 447-465.
308. Sun S, Schiller JH (2007) Angiogenesis inhibitors in the treatment of lung cancer. *Crit Rev. Oncol. Hematol.*, **62**: 93-104.

309. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. *J. Cell Biochem.*, **89**: 462-473.
310. Sundberg C, Thodeti CK, Kveiborg M, Larsson C, Parker P, Albrechtsen R, Wewer UM (2004a) Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. *J. Biol. Chem.*, **279**: 51601-51611.
311. Sundberg C, Thodeti CK, Kveiborg M, Larsson C, Parker P, Albrechtsen R, Wewer UM (2004b) Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. *J. Biol. Chem.*, **279**: 51601-51611.
312. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE, Chung LW (2006) Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. *Cancer Res.*, **66**: 9519-9526.
313. Takeda S, Igarashi T, Mori H, Araki S (2006) Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. *EMBO J.*, **25**: 2388-2396.
314. Takeshita F, Ochiya T (2006) Therapeutic potential of RNA interference against cancer. *Cancer Sci.*, **97**: 689-696.
315. Tlsty TD, Hein PW (2001) Know thy neighbor: stromal cells can contribute oncogenic signals. *Curr. Opin. Genet. Dev.*, **11**: 54-59.
316. Tousseyn T, Jorissen E, Reiss K, Hartmann D (2006) (Make) stick and cut loose--disintegrin metalloproteases in development and disease. *Birth Defects Res. C. Embryo. Today*, **78**: 24-46.
317. Tuxhorn JA, Ayala GE, Rowley DR (2001a) Reactive stroma in prostate cancer progression. *J. Urol.*, **166**: 2472-2483.
318. Tuxhorn JA, Ayala GE, Rowley DR (2001b) Reactive stroma in prostate cancer progression. *J. Urol.*, **166**: 2472-2483.
319. Uria JA, Balbin M, Lopez JM, Alvarez J, Vizoso F, Takigawa M, Lopez-Otin C (1998) Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. *Am. J. Pathol.*, **153**: 91-101.
320. van den HA (1988) Stromal involvement in malignant growth. *Adv. Cancer Res.*, **50**: 159-196.
321. Van Lint P, Libert C (2006) Matrix metalloproteinase-8: cleavage can be decisive. *Cytokine Growth Factor Rev.*, **17**: 217-223.
322. Van Lint P, Libert C (2007) Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. *J. Leukoc. Biol.*, **82**: 1375-1381.



323. Van Roy M, Van Lint P, Van L, I, Wielockx B, Wilson C, Lopez-Otin C, Shapiro S, Libert C (2007) Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFN $\gamma$ -based cancer therapy in mice. *Mol. Cancer Ther.*, **6**: 2563-2571.
324. Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. *Proc. Natl. Acad. Sci. U. S. A.*, **87**: 5578-5582.
325. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML (1999a) METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. *J. Biol. Chem.*, **274**: 23349-23357.
326. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML (1999b) METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. *J. Biol. Chem.*, **274**: 23349-23357.
327. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML (1999c) METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. *J. Biol. Chem.*, **274**: 23349-23357.
328. Vesterinen E, Pukkala E, Timonen T, Aromaa A (1993) Cancer incidence among 78,000 asthmatic patients. *Int. J. Epidemiol.*, **22**: 976-982.
329. Vu TH, Werb Z (2000a) Matrix metalloproteinases: effectors of development and normal physiology. *Genes Dev.*, **14**: 2123-2133.
330. Vu TH, Werb Z (2000b) Matrix metalloproteinases: effectors of development and normal physiology. *Genes Dev.*, **14**: 2123-2133.
331. Wang WM, Ge G, Lim NH, Nagase H, Greenspan DS (2006) TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. *Biochem. J.*, **398**: 515-519.
332. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. *Cancer Res.*, **55**: 514-517.
333. Weaver VM, Gilbert P (2004) Watch thy neighbor: cancer is a communal affair. *J. Cell Sci.*, **117**: 1287-1290.
334. Wewer UM, Morgelin M, Holck P, Jacobsen J, Lydolph MC, Johnsen AH, Kveiborg M, Albrechtsen R (2006) ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. *J. Biol. Chem.*, **281**: 9418-9422.
335. Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE (2006) Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. *J. Thorac. Oncol.*, **1**: S8-12.

336. Wolfsberg TG, Bazan JF, Blobel CP, Myles DG, Primakoff P, White JM (1993b) The precursor region of a protein active in sperm-egg fusion contains a metalloprotease and a disintegrin domain: structural, functional, and evolutionary implications. *Proc. Natl. Acad. Sci. U. S. A.*, **90**: 10783-10787.
337. Wolfsberg TG, Bazan JF, Blobel CP, Myles DG, Primakoff P, White JM (1993a) The precursor region of a protein active in sperm-egg fusion contains a metalloprotease and a disintegrin domain: structural, functional, and evolutionary implications. *Proc. Natl. Acad. Sci. U. S. A.*, **90**: 10783-10787.
338. Wolfsberg TG, Straight PD, Gerena RL, Huovila AP, Primakoff P, Myles DG, White JM (1995) ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. *Dev. Biol.*, **169**: 378-383.
339. Wong GE, Zhu X, Prater CE, Oh E, Evans JP (2001) Analysis of fertilin alpha (ADAM1)-mediated sperm-egg cell adhesion during fertilization and identification of an adhesion-mediating sequence in the disintegrin-like domain. *J. Biol. Chem.*, **276**: 24937-24945.
340. WYNDER EL, GRAHAM EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. *J. Am. Med. Assoc.*, **143**: 329-336.
341. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, Fujisawa-Sehara A (1995a) A metalloprotease-disintegrin participating in myoblast fusion. *Nature*, **377**: 652-656.
342. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, Fujisawa-Sehara A (1995b) A metalloprotease-disintegrin participating in myoblast fusion. *Nature*, **377**: 652-656.
343. Yang J, Wei D, Liu J (2005) Repressions of MMP-9 expression and NF-kappa B localization are involved in inhibition of lung carcinoma 95-D cell invasion by (-)-epigallocatechin-3-gallate. *Biomed. Pharmacother.*, **59**: 98-103.
344. Yang P, Baker KA, Hagg T (2006) The ADAMs family: coordinators of nervous system development, plasticity and repair. *Prog. Neurobiol.*, **79**: 73-94.
345. Yatabe Y, Mitsudomi T (2007) Epidermal growth factor receptor mutations in lung cancers. *Pathol. Int.*, **57**: 233-244.
346. Yi H, Gruszczynska-Biegala J, Wood D, Zhao Z, Zolkiewska A (2005) Cooperation of the metalloprotease, disintegrin, and cysteine-rich domains of ADAM12 during inhibition of myogenic differentiation. *J. Biol. Chem.*, **280**: 23475-23483.
347. Yi M, Ruoslahti E (2001) A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. *Proc. Natl. Acad. Sci. U. S. A.*, **98**: 620-624.
348. Yokoyama H, Wada T, Kobayashi K, Kuno K, Kurihara H, Shindo T, Matsushima K (2002) A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-

- 1 null mutant mice develop renal lesions mimicking obstructive nephropathy. *Nephrol. Dial. Transplant.*, **17 Suppl 9**: 39-41.
349. Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y (1998a) Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. *J. Biol. Chem.*, **273**: 7345-7350.
350. Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y (1998b) Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. *J. Biol. Chem.*, **273**: 7345-7350.
351. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA (2006d) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*, **10**: 39-50.
352. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA (2006b) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*, **10**: 39-50.
353. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA (2006c) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*, **10**: 39-50.
354. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA (2006a) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. *Cancer Cell*, **10**: 39-50.
355. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. *Immunity.*, **12**: 121-127.
356. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat. Rev. Cancer*, **5**: 263-274.
357. Zucker S, Cao J, Chen WT (2000a) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. *Oncogene*, **19**: 6642-6650.
358. Zucker S, Cao J, Chen WT (2000b) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. *Oncogene*, **19**: 6642-6650.

## PUBLICATIONS PERSONNELLES

Cataldo DD, Gueders MM, **Rocks N**, Sounni NE, Evrard B, Bartsch P, Louis R, Noel A, Foidart JM. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors, *Cell Mol Biol*, 2003;49(6):875-84.

Cataldo D, Gueders M, Munaut C, **Rocks N**, Perin F, Caulier C, Colige C, Lambert Ch, Bartsch P, Foidart JM, Noel A, Louis R. Matrix Metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 expression in the sputum of asthmatics and COPD. *Allergy*, 2003; chap 41:301-305.

Cataldo D, Gueders M, Munaut C, **Rocks N**, Bartsch P, Foidart JM, Noel A, Louis R. Matrix metalloproteases and tissue inhibitor of matrix metalloproteases mRNA transcripts in the bronchial secretions of asthmatics. *Lab Invest*, 2004;84(4):418-24.

Noel A, Maillard C, **Rocks N**, Jost M, Chabottaux V, Sounni NE, Cataldo D, Foidart JM. Membrane associated proteases and their inhibitors in tumor angiogenesis. *J Clin pathol*, 2004;57(6):577-584.

Gueders MM, Balbin M, **Rocks N**, Foidart JM, Gosset P, Louis R, Shapiro S, Lopez-Otin C, Noel A, Cataldo DD. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation, *J Immunol*, 2005;175(4):2589-97.

**Rocks N**, Paulissen G, Polette M, Gueders M, Munaut C, Foidart JM, Noel A, Birembaut P, Cataldo D. Expression of A Disintegrin and Metalloprotease (ADAM) enzymes in human non small cell lung carcinomas (NSCLC). *British J Cancer*, 2006; 94(5):724-30.

Paulissen G, **Rocks N**, Gosset P, Foidart J-M, Noel A, Louis R, Cataldo D. Expression of Adamalysin proteases (A Disintegrin and Metalloprotease) and their inhibitors in sputum from asthmatics, *Molecular Medecine*, 2006;12(7-8):171-9.

**Rocks N**, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer, *Biochimie*, 2008;90(2):369-79.

Gueders MM, Bertholet P, Perin F, **Rocks N**, Maree R, Botta V, Louis R, Foidart JM, Noel A, Evrard B, Cataldo DD. A novel formulation of inhaled doxycycline reduces allergen-induced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. *Biochem Pharmacol*, 2008;75(2):514-26.

**Rocks N**, Estrella C, Paulissen G, Quesada-Calvo F, Gilles C, GuEderS M, Crahay C, Foidart JM, Gosset P, Noel A, Cataldo D. The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis. *Cell Proliferation*, en révision.

**Rocks N**, Paulissen G, Quesada-Calvo F, Alvarez Gonzalez ML, Gueders M, Hacha J, Gilles C, Foidart JM, Noel A, Cataldo D. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. *Cancer Research*, *soumise pour publication*.

Estrella C, **Rocks N**, Paulissen G, Quesada-Calvo F, Vilain E, Lassalle P, Tillie-Leblond I, Cataldo D, Gosset P. Increased expression of A Disintegrin and Metalloprotease (ADAM)-12 in allergic rhinitis: implication in neutrophil recruitment by airway epithelial cells. *En préparation*.